Modified GRF (1-29) + Ipamorelin + GHRP-2

1 Identity

Fixed-ratio three-component article: one 29-residue C-terminally amidated GHRH analogue co-lyophilized with two short synthetic peptides of the GHRP class. No metal, disulfide, acyl chain or conjugate. CJC-1295 proper is the DAC-bearing maleimide conjugate, 279.296 Da heavier and a different article.

Sequence

Per component, cross-referenced. Modified GRF (1-29) Y-(D-A)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2, 29 residues, no sulfur. Ipamorelin Aib-His-D-2-Nal-D-Phe-Lys-NH2. GHRP-2 H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. All three carry a C-terminal primary amide; a free-acid form of any is a specified impurity, not a synonym.

Molecular formula

Per component; a mixture has no combined formula and none is written. Modified GRF (1-29) C152H252N44O42; ipamorelin C38H49N9O5; GHRP-2 C45H55N9O6, all free base, each commonly supplied as an acetate and GHRP-2 also as the mono-trifluoroacetate C47H56F3N9O8. Counterion is a measured finding per component: TFA at high mass fraction on one component and acetate on another passes a gross-weight check while the ratio is already out.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: Modified GRF (1-29) 3,367.954 Da; ipamorelin 711.868 Da; GHRP-2 817.992 Da. At a nominal 2 mg + 2 mg + 2 mg fill, 6 mg total, the 1.0 : 1.0 : 1.0 mass ratio is a molar ratio of 1.00 : 4.73 : 4.12 - 0.59383, 2.80951 and 2.44501 micromol. An equal-mass presentation of a 3.4 kDa peptide against two sub-kilodalton peptides is nowhere near equimolar, and a document treating the mass ratio as a molar ratio is wrong on its face.

Monoisotopic mass

Per component. Modified GRF (1-29) 3,365.89358 neutral, observed multiply charged, [M+3H]3+ 1,122.97180, [M+4H]4+ 842.48067. Ipamorelin 711.3857, [M+H]+ 712.3930. GHRP-2 817.4275, [M+H]+ 818.4348. Three separations govern acceptance: Modified GRF against sermorelin at 10.021 Da average with sermorelin carrying the only sulfur; against CJC-1295 at 279.296 Da; ipamorelin against GHRP-2 at 106.124 Da. A single blend 'molecular weight' is not a chemical fact and is never printed.

Salt / variant note

(1) The name fork: Modified GRF (1-29) at 3,367.954 against CJC-1295 (DAC:GRF) 3,647.250. (2) Sermorelin at 3,357.933 is 10.021 Da lighter and carries one sulfur in Met27 that this article's Leu27 lacks - any sulfur indicates sermorelin-family material; also (D-Ala2)-GRF(1-29) amide, the mono-substituted variant, a third distinct molecule.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P3 — panel definitionfor all three, run per component rather than once. P3 is engaged three times over: D-Ala2 in Modified GRF (1-29); Aib1, D-2-Nal3, D-Phe4 in ipamorelin; D-Ala1, D-2-Nal2, D-Phe5 in GHRP-2. A chiral method is mandatory and is run against each component's own expected D-content, never a pooled figure

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component, is graded on that component's record and is cross-referenced from here rather than restated: the Modified GRF (1-29) file is thin under this designation and traces to the Salk substitution chemistry of the 1980s and 1990s; the ipamorelin file is preclinical in substance, its sponsor program discontinued and no approval anywhere; the GHRP-2 file carries a human literature by identifier and is graded B/C, GHRP-2 being the active moiety of a medicine registered in Japan.

4 Storage & specification

Storage

White to off-white co-lyophilized solid in Type I amber glass with a PTFE-lined closure, nitrogen headspace, in-pack desiccant, non-sterile with no sterility claim and not an injection presentation. Store at -20 degrees C plus or minus 5 degrees C, tightly closed, desiccated, protected from light. Amber glass or foil overwrap is not precautionary: the naphthalene rings of ipamorelin and GHRP-2 and the GHRP-2 indole are photolabile, so two of three components carry a light liability. Sealed vials are equilibrated to ambient temperature before opening, the acetate salts being hygroscopic.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light from QA release, taken as the shortest of the three component intervals, each itself a provisional 24 months. The blend runs its own protocol and inherits no component study, with a mandatory 6-month interim pull on each of the first three lots. Trended attributes are chosen for the mixture: per-component net content, the measured ratio, aspartimide and iso-aspartate at Asp3 and Asp25 of the 29-mer, oxidation of the GHRP-2 indole, C-terminal amide hydrolysis on all three, water, counterion and any new peak above 0.10 percent.